These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7898167)

  • 1. Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease.
    Greig NH; Pei XF; Soncrant TT; Ingram DK; Brossi A
    Med Res Rev; 1995 Jan; 15(1):3-31. PubMed ID: 7898167
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenserine Axonyx.
    Thatte U
    Curr Opin Investig Drugs; 2005 Jul; 6(7):729-39. PubMed ID: 16044670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
    Greig NH; Sambamurti K; Yu QS; Brossi A; Bruinsma GB; Lahiri DK
    Curr Alzheimer Res; 2005 Jul; 2(3):281-90. PubMed ID: 15974893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
    Greig NH; De Micheli E; Holloway HW; Yu QS; Utsuki T; Perry TA; Brossi A; Ingram DK; Deutsch J; Lahiri DK; Soncrant TT
    Acta Neurol Scand Suppl; 2000; 176():74-84. PubMed ID: 11261809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
    Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
    J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease.
    Crismon ML
    Pharmacotherapy; 1998; 18(2 Pt 2):47-54; discussion 79-82. PubMed ID: 9543465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of (+)-phenserine using an interrupted Fischer indolization reaction.
    Schammel AW; Chiou G; Garg NK
    J Org Chem; 2012 Jan; 77(1):725-8. PubMed ID: 22098120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of phenserine analogues and evaluation of their cholinesterase inhibitory activities.
    Shinada M; Narumi F; Osada Y; Matsumoto K; Yoshida T; Higuchi K; Kawasaki T; Tanaka H; Satoh M
    Bioorg Med Chem; 2012 Aug; 20(16):4901-14. PubMed ID: 22831800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbial transformation of N-heptyl physostigmine, a semisynthetic alkaloid inhibitor of cholinesterase.
    So L; White R; Arison B; Petuch B; Schwartz MS; Cheng H; Monaghan R; Chen TS
    J Ind Microbiol; 1995 Aug; 15(2):108-11. PubMed ID: 7576461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.
    Kamal MA; Greig NH; Alhomida AS; Al-Jafari AA
    Biochem Pharmacol; 2000 Aug; 60(4):561-70. PubMed ID: 10874131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative QSAR analysis of acetylcholinesterase inhibitors currently studied for the treatment of Alzheimer's disease.
    Recanatini M; Cavalli A; Hansch C
    Chem Biol Interact; 1997 Aug; 105(3):199-228. PubMed ID: 9291997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Was phenserine a failure or were investigators mislead by methods?
    Becker RE; Greig NH
    Curr Alzheimer Res; 2012 Dec; 9(10):1174-81. PubMed ID: 23227991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
    Håkansson L
    Acta Neurol Scand Suppl; 1993; 149():7-9. PubMed ID: 7907455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
    Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
    Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
    Kamal MA; Klein P; Yu QS; Tweedie D; Li Y; Holloway HW; Greig NH
    J Alzheimers Dis; 2006 Sep; 10(1):43-51. PubMed ID: 16988481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action.
    Yu Q; Holloway HW; Flippen-Anderson JL; Hoffman B; Brossi A; Greig NH
    J Med Chem; 2001 Nov; 44(24):4062-71. PubMed ID: 11708910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?
    Becker RE; Greig NH
    Alzheimers Dement; 2013 Jan; 9(1):50-7. PubMed ID: 22465172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues.
    Yu QS; Pei XF; Holloway HW; Greig NH; Brossi A
    J Med Chem; 1997 Aug; 40(18):2895-901. PubMed ID: 9288171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
    Martinez A; Castro A
    Expert Opin Investig Drugs; 2006 Jan; 15(1):1-12. PubMed ID: 16370929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.